Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

NCT04566393 is registered in ClinicalTrials.gov with xCures as lead sponsor.

NCT NCT04566393
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04566393 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
Lead sponsor
xCures
Phase
Expanded access
Overall status
Available
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, braf gene mutation, cholangiocarcinoma, colorectal cancer, erk mutation, esophageal cancer, gastric cancer, glioblastoma, head and neck cancer, hepatocellular carcinoma, hras gene mutation, kras activating mutation, mapk gene mutation, mek mutation, melanoma, non small cell lung cancer, nras gene mutation, ovarian cancer, pancreatic cancer, small bowel cancer, thyroid cancer